Earnings Call · Q2 FY2021·2021-08-04

Q2 21EPS 0.00%·Rev n/aQ1 21EPS +5.17%·Rev n/aQ4 20EPS -42.86%·Rev n/aQ3 20EPS +10.45%·Rev n/a⚠ consensus missing

TherapeuticsMD, Inc. TXMD

Lisa Wilson — Investor Relations

Rob Finizio — Chief Executive Officer

James D’Arecca

Dawn Halkuff — Chief Commercial Officer

−7.1%1d on move date−6.7% vs SPY3d−3.1%5d−6.1%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TXMD calls or request research access.

More TXMD calls Browse calls Request research access